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Abstract 
Purpose: Image-guided systems that fuse magnetic resonance imaging (MRI) with three-dimensional (3D) ultrasound 
(US) images for performing targeted prostate needle biopsy and minimally-invasive treatments for prostate cancer are 
of increasing clinical interest. To date, a wide range of different accuracy estimation procedures and error metrics have 
been reported, which makes comparing the performance of different systems difficult.  
Methods: A set of 9 measures are presented to assess the accuracy of MRI-US image registration, needle positioning, 
needle guidance, and overall system error, with the aim of providing a methodology for estimating the accuracy of 
instrument placement using a MR/US-guided transperineal approach.  
Results: Using the SmartTarget fusion system, an MRI-US image alignment error was determined to be 2.0±1.0 mm 
(mean ± SD), and an overall system instrument targeting error of 3.0±1.2 mm. Three needle deployments for each target 
phantom lesion was found to result in a 100% lesion hit rate and a median predicted cancer core length of 5.2 mm. 
Conclusions: The application of a comprehensive, unbiased validation assessment for MR/TRUS guided systems can 
provide useful information on system performance for quality assurance and system comparison. Furthermore, such an 
analysis can be helpful in identifying relationships between these errors, providing insight into the technical behaviour 
of these systems. 




The widespread introduction of  magnetic resonance imaging (MRI) for detecting, staging, and localising prostate can-




needle biopsy and minimally-invasive treatments  [1, 2]. The accuracy of such systems has been the subject of a number 
of previous phantom studies, with mean errors between 2 and 3mm commonly reported [3–8]. However, the error met-
rics adopted vary considerably. Furthermore, few studies have attempted to estimate needle/instrument placement ac-
curacy for procedures where the needle/instrument is inserted via the perineum. Among such transperineal procedures 
are a wide range of minimally-invasive surgical treatments, such as cryotherapy and injectable drug therapies. A further 
problem is that accuracy measures are typically difficult to relate to clinically meaningful measures, such as tumour/le-
sion hit-rate. Although phantom experiments are generally performed under idealised conditions, where, for example, 
the phantom motion does not represent tissue motion encountered in vivo, it is still important to estimate the accuracy 
of a fusion system to provide an indication of its performance under “perfect” conditions (i.e. where sources of error 
are well controlled) to enable comparison between different systems and for the purposes of quality assurance. In this 
paper, we present a series of error metrics to characterise the accuracy of fusion systems for guiding transperineal 
procedures. 
Materials and Methods 
Accuracy Validation Method 
 
Figure 1. Schematic overview of the workflow of a MR-US guidance software. 
Figure 1 illustrates a typical workflow for an MRI-US fusion system used to place one or more needles/instruments 
into US-visible, target lesions in the phantom. To eliminate bias introduced when an operator targets an US-visible 
lesion, the overall gain on the B-mode of the US scanner may be reduced until lesions are no longer visible but the 
needles or similarly strongly-reflective instruments remain identifiable in the US images. This procedure is also effec-
tive at reducing the visibility of needle tracks from previous instrument insertions, which can be an additional source of 
bias. Once the desired number of instruments have been inserted, 3D US imaging of the phantom is performed to enable 
the 3D position of each instrument to be determined with respect to the target. Here, we refer to this image as a “vali-
dation volume”. Two validation volumes are obtained after instrument placement – one with the US scanner gain set 
low so that the instrument artefacts are minimised, and one after the gain has been increased so that lesions are clearly 
visible – this helps to ensure that both the instrument tip, lesions, and lesion centres are determined as accurately as 
possible. To calculate the error metrics introduced in the next section, the validation volumes are analysed to define the 




here to refer to the ground truth point target location, which for convenience is assumed to be at the centroid of the 
target phantom lesion. 
Error Metrics  
In this section, a set of 3D error metrics for quantifying the system accuracy of an MR/TRUS fusion system related to 
different error sources are defined. These metrics are illustrated graphically in Figure 2. 
 
Figure 2. Measures used for the validation: 1 - Target registration error (TRE). 2 - Surface overlap error. 3 - Overall 
targeting error. 4 – Overall procedural error. 5 – Needle/instrument deflection error. 6 – Template grid error. 7 - Tar-
geting error excluding needle deflection error. 8 - Targeting error excluding template grid error. 
Target Registration Error (Measure 1) 
The MRI-TRUS target registration error (TRE) is defined as the Euclidean distance between the centre of the TRUS 
true target lesion (defined in the validation image volume) and the centre of the registered target lesion. We assume here 
that the target lesion centre point is not used in the registration of the MRI and TRUS images. Most commonly, the 
prostate surfaces, defined in both MRI and TRUS images, are registered. The TRE calculated for one or more target 
lesions is then independent of the points used to calculate the registration transformation. Since this measure depends 
on the image resolution, all imaging parameters must be reported. 
Surface Overlap Error (Measure 2) 
The MRI-TRUS lesion overlap assesses the accuracy of the registration in predicting the location of regions of interest. 
Here we adopt the commonly used Dice Similarity Coefficient (DSC), which is calculated in the validation image vol-
ume. Additionally, the agreement between the MRI and US surfaces of the prostate gland, in terms of distance between 
points on the gland (identified in TRUS images) and the registered gland surfaces, is also calculated to provide a refer-
ence point on the registration algorithmic performance. Unlike the lesion overlap (Measure 2) or TRE (Measure 1), it 
is important to note that this measure does not provide an independent measure to assess registration accuracy for the 
purposes of instrument targeting when MRI and TRUS surfaces are registered. The surface distance is defined as the 
root-mean-square (RMS) distance between the points identified in both surfaces (TRUS and registered MRI). 
Overall Targeting Error (Measure 3) 
The overall targeting error, based on physical needle-tip placement, is defined as the Euclidean distance between the 
needle tip position and the physical centre of the true target lesion identified in the same TRUS image volume. This 




Procedural Errors (Measures 4 - 6) 
The position of the biopsy needle is subject to bending, deflection and uncertainty in insertion depth, which can be 
measured collectively by the distance between the “true”- and the “planned” needle tips. This is termed the needle 
deflection error (Measure 5). In case of using a fixed brachytherapy template grid, the needle placement is further 
restricted by the position of the grid relative to the phantom. This template grid error can be measured by the distance 
between the “planned” needle tip and the registered lesion centre, i.e. the target upon which the calculation of the needle 
position is based (Measure 6). The overall procedural error – i.e. the error due to the uncertainty in needle placement 
during the procedure – is defined as the distance between the registered target centre and the “true” needle tip (Measure 
4), combining Measures 5 and 6. 
Decoupled Targeting Errors (Measures 7 - 8) 
The overall targeting error (Measure 3) includes the registration error (TRE; Measure 1) and the overall procedural error 
(Measure 4). In some applications, such as biopsy or brachytherapy, needle deflection may be significant [9]. For such 
applications, de-coupling the overall procedural error into template and needle deflection (Measures 6 and 5 respec-
tively) enables these two component errors to be excluded from the overall targeting error. A decoupled guidance error, 
including only the template grid error (Measure 6) without the contribution of the needle deflection error (Measure 5), 
may be defined as the distance between the true target lesion and the planned needle- (or instrument-) tip. This error 
measure is referred to here as the targeting error excluding needle/instrument deflection error and is shown as Measure 
7 in Figure 2. Similarly, another decoupled targeting error including only deflection error (Measure 5), which is equiv-
alent to the targeting error, excluding the template grid error, may be measured as the distance between the true target 
lesion and a virtual needle tip location, assuming an idealised needle/instrument trajectory without deflection (following 
registration, if the template grid was adaptable and moved to the same position of the registered target in the transverse 
plane). The position of this virtual needle/instrument tip position is estimated by adding the 3D position of the registered 
target to the independently measured deflection error in 3D. This error is denoted as Measure 8 and provides an estimate 
of the optimal overall system guidance error only with needle/instrument deflection. 
 
Biopsy-specific Measures 
For needle biopsy, the cancer core length (CCL), defined as the physical length of cancerous tissue in a tissue sample, 
and the lesion hit rate are two important clinical measures that have a direct bearing on the performance of targeted 
prostate biopsy as a diagnostic test. Such measures are straightforward to calculate from the phantom data. Therefore, 
if possible, we propose to estimate additional measures including the predicted CCL (for each needle insertion), lesion 
hit rate, maximum CCL, and total CCL (for multiple needle insertions), based on the point-to-point distance errors 
calculated for the measures defined above. In this work, the CCL is calculated by finding the length of the intersection 
between the needle trajectory and the true lesion segmented from the validation volume(s). 
Error Analysis 
A comprehensive error analysis in which distributions and summary statistics were calculated for each error and each 
needle insertion. Statistical tests comparing each decoupled targeting errors (Measure 7 and 8) and the overall targeting 
error (Measure 3) were performed to reveal the effect of needle deflection or fine-adjustment of the template grid posi-




(GoF) and Kolmogorov-Smirnov (K-S) GoF). When the normality tests failed, in addition to the Student’s t-test, results 
from a non-parametric test (Wilcoxon rank sum test) were also reported. 
Example Application 
We tested a research version of the commercially available SmartTarget guidance system, developed by our research 
group (SmartTarget Ltd., London, UK). The equipment was set up as per a template-guided transperineal biopsy using 
a disposable brachytherapy template grid (CIVCO Medical Solutions, Iowa, USA) attached to an US probe stepper. The 
template contained a 13 by 13 grid of holes, spaced 5 mm apart in both directions. We used the CIRS 053-MM prostate 
training phantom (Computerized Imaging Reference Systems, Inc. Norfolk, Virginia, USA), compatible with US, CT 
and MR imaging. This phantom contains three hypoechoic spherical objects, with a volume of 0.5 cc, randomly-placed 
within the prostate to represent three lesions. The phantom was scanned with a Philips Archieva 3.0 Tesla MR machine 
to get the T2-weighted MRI images for the pre-operative planning with a voxel size of 0.38 × 0.38 × 1.00 mm and a 
total of 55 transversal slices. Three Bard® Max-Core® disposable core biopsy needle guns were used, each with a 16 
cm, 18-gauge needle (Bard Biopsy Systems, Arizona, USA). Briefly, a patient specific model was generated during pre-
operative planning using the method described in [10] and registered to a reconstructed 3D TRUS volume [11]. Then, 
three biopsy needles were inserted into the three optimal 3 template grid co-ordinates calculated and displayed, follow-
ing the validation procedure outlined earlier.  
Results 
In this section, accuracy results for the system tested based on the measures introduced earlier are summarised. 
MR-US image Registration Accuracy 
The mean (± SD) TRE and lesion surface overlap (Measures 1 and 2) were 2.03 ± 0.98 mm and 68.77 ± 14.25%, 
respectively. Histograms of these errors are shown in Figure 3 (a) and (b). The mean distance between the manually-
defined TRUS prostate boundary points and the registered MR model was 0.67 ± 0.04 mm (see Figure 3 (c)). 
 
(a) (b)  (c)  
Figure 3. Histograms and estimated error distribution of: a) the TRE (Measure 1); b) the surface overlap error between 
registered and true lesion (Measure 2); and c) the point-to-surface distance between the registered model and the user-
defined US points. 
A χ2 goodness-of-fit (GoF) test confirms that the cross-tabulated TRE and point-to-surface distance values are 
statistically independent (p<0.0001). This suggests that the measure of gland surface agreement may not be appropriate 
to replace the role of the independent TRE in assessing registration accuracy. However, the point-to-surface distance 
provides useful real-time feedback to indicate the algorithmic performance of the MR-TRUS registration (i.e. how well 





The overall procedural error (Measure 4) for the first targeted needle-tip was 2.89 ± 1.24 mm (mean ± SD), and 4.01 ± 
1.45 mm over all three inserted needles. As expected, the second and the third targeted points resulted in larger errors 
due to the physical constraints of the template grid, which means that these tend to be further from the centre of the 
lesion. Procedural errors, including overall error, template and needle deflection errors are summarised in  
Table 1.  
Both χ2 GoF and Kolmogorov-Smirnov (K-S) GoF tests failed to reject the null hypothesis that the difference 
between the procedural error and the overall targeting error follow a normal distribution (χ2 p=0.1229, K-S p=0.9226). 
Paired t-tests between procedural errors and overall targeting error (Measure 3) show that: a) there is statistically sig-
nificant difference between the overall procedural error and the overall targeting error (p=0.0282), which means that 
the procedural error contributed towards the overall targeting error, and b) there is statistically significant difference 
between the template error and the overall targeting error (p<0.0001) and also between the needle deflection error and 
the overall targeting error (p=0.0273), indicating that neither the template nor the needle deflection errors are negligible. 
A further χ2 GoF test failed to reject that there is statistical significant dependence between the procedural error and 
TRE (p=0.3391). This suggests that the needle positioning may not be necessarily independent of registration error. 
This is probably because both errors may be affected by some properties of the target, such as the phantom material 
properties and the relative spatial locations of the targets of interest. 
 
Table 1. A summary of the mean (± SD) and median [25th 75th percentiles] numerical procedural errors (in mm). 
Order of needle placement Overall procedural error Needle deflection error Template error 
 Mean Median Mean Median Mean Median 
1st needle 2.9±1.2 3.3 [1.8 4.0] 3.7±0.7 3.7 [3.2 4.0] 4.4±1.4 4.6 [3.0 5.3] 
2nd needle 4.7±1.1  4.5 [4.1 5.3] 3.6±1.0 3.6 [3.3 4.2] 6.2±2.0 7.0 [5.2 7.4] 
3rd needle 4.5±1.3 4.3 [3.5 4.9] 3.8±0.9 3.7 [3.2 4.3] 5.5±3.0 6.7 [2.6 7.7] 
All 4.0±1.5 4.2 [3.1 4.8] 3.7±0.9 3.7 [3.2 4.2] 5.4±2.3 5.5 [3.0 7.2] 
 
Targeting Errors 
Targeting errors (Measures 3, 7 and 8) are summarised in Error! Reference source not found.. A histogram of the 
corresponding errors for each needle placement is shown in Figure 4. In 93% of the cases, the lesion was hit with the 
first needle; a 100% lesion hit rate was achieved when all 3 deployed needles were taken into account. 
 
Table 2. A summary of the mean (± SD) and median [25th 75th percentiles] numerical targeting errors (in mm). 
Order of needle 
placement 
Overall targeting error Targeting error excluding 
needle deflection error 
Targeting error excluding 
template error 
 Mean Median Mean Median Mean Median 
1st needle 3.0±1.2 3.1 [2.2 3.2] 5.5±1.0 5.2 [5.0 5.5] 3.0±1.1 2.9 [2.2 3.6] 
2nd needle 5.1±1.3 5.3 [4.9 5.9] 7.3±2.1 8.4 [6.6 8.6] 2.6±0.9 2.4 [2.1 3.0] 
3rd needle 4.9±1.5 4.6 [3.7 6.0] 6.6±3.1 8.9 [2.9 9.2] 3.1±1.3 3.1 [2.5 3.6] 





 (a)   (b)  
(c)    (d)  
Figure 4. Histogram and estimated error distribution of overall targeting errors for: a) all data; b) the 1st needle, c) the 
2nd needle, and d) the 3rd needle (in mm). 
 
χ2 GoF tests were performed between the overall targeting error and procedural error (p=0.2381) and between 
overall targeting error and TRE (p=0.3391). This confirms that both the TRE and procedural error contributed signifi-
cantly towards the overall targeting error. The χ2 GoF test rejected the null hypothesis that the difference between the 
targeting error excluding needle deflection error (Measure 7) and the overall targeting error follows a normal distribution 
(p=0.0188), while the single sample Kolmogorov-Smirnov GoF test failed to reject the hypothesis (p=0.1042). While, 
both the χ2 GoF test and the sample Kolmogorov-Smirnov GoF test, failed to reject the null hypothesis that the difference 
between the targeting error excluding template error and the overall targeting error follows a normal distribution (χ2 
p=0.1736, K-S p=0.6960). Paired t-tests and non-parametric Wilcoxon rank sum tests were performed to test if there is 
significant difference between the overall targeting error (Measure 3) and Measures 7 and 8. Results show that the 
targeting error excluding needle deflection error is statistically significant different than the overall targeting error (both 
tests p<0.0001). Additionally, although results show a significant difference between the targeting error excluding tem-
plate error (Measure 8) and the overall targeting error (both tests p<0.0001) considering all needles, there is no signifi-
cant increase in the overall targeting error considering only the first needle (t-test p=0.9095, Wilcoxon test p=1.0). The 
test also accepts the hypothesis that the difference is significantly smaller than 2 mm between these two measures for 
all the needles. 
 
Biopsy-specific Measures 
A summary of the mean predicted CCL, the maximum CCL, and total CCL (for multiple needle insertions) are shown 
in Table 3.  
Table 3. A summary of the median CCL [25th 75th percentiles], maximum CCL (MCCL), and total CCL (in mm) 
Lesion CCL  MCCL Total CCL 
1st lesion 2.7 [0.0 6.7] 8.14 8.92 
2nd lesion 5.2 [2.3 7.4] 7.61 13.85 
3rd lesion 6.9 [0.0 7.8] 8.03 15.27 





In this paper we propose a practical validation procedure that enables a comprehensive set of quantitative measures to 
be estimated to assess the accuracy of a prostate MR/TRUS fusion system.  
We chose point-to-point distance errors instead of target-point to needle-track-segment distances so that the tip 
of the instrument was guided to a point target (generally, the centre of the lesion or other location). Distances in 2D/3D 
between a line (or line segment) that represents an instrument trajectory, and a point target, or between two lines, provide 
less informative measures of targeting error than the distance between two points.  
 The phantom used in this study provides a basis for examining system accuracy under idealised “laboratory” 
conditions. However, its mechanical properties may differ significantly from human tissue and motion encountered in 
vivo. This poses a challenge for estimating the “real-world” registration accuracy, as well as the overall in vivo targeting 
accuracy, but arguably the validation under controlled conditions using a phantom is still important for quality assurance 
purposes, system comparison, and understanding the contributions of different error sources. Note that, the set of 
measures can be used with different phantoms. However, if the intention is to compare the accuracy of different fusion 
systems, the same model of phantom should be used in the evaluation of each system to ensure a fair comparison. 
We have reported results using non-parametric Wilcoxon sum rank tests when the normality tests rejected the 
null hypothesis that the data followed a normal distribution. However, we would like to note that both the normality 
tests and the non-parametric tests may lack of statistical power with small data size, which has to be addressed in the 
experiment design prior to obtaining the results. Nevertheless, such validation experiments complement further clinical 
validation studies, which focus on clinical outcomes and typically require a reasonable level of system accuracy to be 
established to ensure safety and maximise the achievable efficacy of the procedure [12–15].  
Another limitation relates to the way in which 3D TRUS images are used for validation purposes, which is 
known to sometimes present problems in accurately localising needle/instrument tips due to image artefacts. On balance, 
US provides a simple and immediate means of acquiring a 3D image of instruments in situ, which avoids errors intro-
duced after transferring to, and imaging with, other modalities, such as CT.  
An interesting finding from the application of the validation procedure was the dependency between registra-
tion error and procedural error using the investigated guidance system. This may be due to the fact that the lesion has 
some material or mechanical properties that may bias both registration and needle positioning errors. This may lead to 
a propagation model being formulated to predict the TRE, which is not easily available in real patient data validation or 
during the procedure as an accuracy feedback.  
 To date, neither the relationship between different types of errors, nor the contribution of each error to the 
overall targeting error of a system, has been reported systematically. Therefore, it is difficult to draw conclusions that 
can inform decisions on the adoption or improvement of a particular guidance system for specific clinical applications. 
Conclusions 
In this paper, we have proposed and demonstrated the application of a comprehensive, unbiased validation assessment 
for MR/TRUS guided targeting systems for prostate transperineal biopsy and focal therapy. The error analysis indicated 
that the proposed procedure can provide useful information on system performance for quality assurance, system com-
parison, evaluating the magnitudes of different sources of errors, by comparing these errors (for instance to identify 
workflow and algorithmic improvements), and identifying relationships between these errors that provide insight into 
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